BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 12, 2024
See today's BioWorld
Home
» Sosei, Allergan pause Alzheimer's program to probe preclinical toxicity
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Sosei, Allergan pause Alzheimer's program to probe preclinical toxicity
Sep. 19, 2018
By
Nuala Moran
No Comments
LONDON – Another Alzheimer's disease program has run into problems, with Sosei Group Corp. and partner Allergan plc halting development of HTL-0018318 after cynomolgus monkeys in a toxicology study developed neoplastic tumors.
BioWorld